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A B S T R A C T
Introduction. Recently, testosterone (T) has been shown to be associated with premature ejaculation (PE) symptoms
in the literature. Furthermore, studies suggest that the etiology of PE is partly under genetic control.
Aim. The aim of this study was to reassess ﬁndings suggesting an association between testosterone (T) and a key
symptom of PE, ejaculation latency time (ELT), as well as exploratively investigating associations between six
androgen-related genetic polymorphisms and ELT.
Materials and Methods. Statistical analyses were performed on a population-based sample of 1,429 Finnish men
aged 18–45 years (M = 26.9, SD = 4.7). Genotype information was available for 1,345–1,429 of these (depending on
the polymorphism), and salivary T samples were available from 384 men. Two androgen receptor gene-linked, two
5-alpha-reductase type 2-gene-linked, and two sex hormone-binding globuline gene-linked polymorphisms were
genotyped.
Main Outcome Measures. Ejaculatory function was assessed using self-reported ELT.
Results. We found no association between salivary T levels and ELT. We found a nominally signiﬁcant association
between a 5-alpha-reductase type 2-gene-linked polymorphism (rs2208532) and ELT, but this association did not
remain signiﬁcant after correction for multiple testing. One single nucleotide polymorphism in the sex hormone-
binding globulin gene (rs1799941) moderated (signiﬁcantly after correction for multiple testing) the association
between salivary T and ELT, so that A:A genotype carriers had signiﬁcantly lower salivary T levels as a function of
increasing ELT compared with other genotype groups.
Conclusions. We were unable to ﬁnd support for the hypothesis suggesting an association between T levels and ELT,
possibly because of the low number of phenotypically extreme cases (the sample used in the present study was
population based). Our results concerning genetic associations should be interpreted with caution until replication
studies have been conducted. Jern P, Westberg L, Ankarberg-Lindgren C, Johansson A, Gunst A, Sandnabba
NK, and Santtila P. Associations between salivary testosterone levels, androgen-related genetic
polymorphisms, and self-estimated ejaculation latency time. Sex Med 2014;2:107–114.
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Introduction
Ejaculatory problems are common in thepopulation, and problems relating to prema-
ture ejaculation (PE) are the most common male
sexual complaints, with around 30% of men pre-
senting subjective concerns regarding their ejacu-
latory function [1,2]. In the past two decades,
increasingly ambitious efforts have been under-
taken to elucidate the etiology of PE and the
underlying mechanisms that trigger the ejacula-
tory reﬂex, but most of the variation in PE etiology
remains poorly understood.
While it is well documented that sex steroids
play a role in the regulation of most, if not all,
aspects of male sexual behavior [3], the exact role of
testosterone in the regulation of ejaculatory func-
tion is yet unclear. Studies conducted on animals
have found no difference in plasma concentrations
of T between sexually sluggish rats with intact and
disrupted ejaculatory function [4]. Furthermore,
sexually sluggish rats received no improvement in
ejaculatory function when treated with subcutane-
ous T [5]. However, in humans, there is some
evidence for direct T involvement in ejaculatory
function, with indications of higher levels of both
free and total T in PE patients [3,6,7]. In a study of
2,652 patients, including 674 with symptoms of PE
and 194 with symptoms of delayed ejaculation
(DE), signiﬁcant effects of small effect size were
observed indicating elevated T levels in PE
patients, and decreased T levels in DE patients [6].
This effect appeared as a linear function of severity
of ejaculatory problems, so that individuals with the
most severe PE problems also displayed the highest
T values, and individuals with the most severe DE
problems displayed the lowest T levels. In addition,
Corona and his associates [7] noted similar effects
of thyrotropin and prolactin, but in the opposite
direction (e.g., so that high levels of these were
associated with more severe DE symptoms). In
addition, in a study of men in couples with infertil-
ity, levels of free T were found to be positively
associated with elevated PE scores [8]. In summary,
results from empirical studies regarding the role of
T in ejaculatory function are inconclusive.
It is conceivable that sex steroid-related genetic
polymorphisms could inﬂuence ejaculatory func-
tion in men in two ways: directly (i.e., exert a main
effect on either T levels or ejaculatory function) or
indirectly through moderation of the association
between, for example, T and ejaculatory function.
Of the androgen-related genetic polymorphisms,
the CAG repeat polymorphism in the androgen
receptor gene (arCAG) has been extensively
studied in other contexts. Furthermore, the
arCAG polymorphism has been shown to moder-
ate the association between T and various pheno-
types and conditions, for example, andropausal
symptoms [9], symptoms of mood disorders
[10,11], and insulin sensitivity [12]. However,
other genes could also conceivably play a direct or
indirect role in the regulation of ejaculatory func-
tion. Functional polymorphisms in gene coding
for 5-alpha-reductase type 2 (SRD5A2), a sub-
stance that processes T into the more potent
dihydrotestosterone (DHT), and sex hormone-
binding globulin (SHBG), which binds and inhib-
its the function of sex hormones (particularly T
and DHT), are of particular interest given their
central role in sex hormone regulation. For
example, SHBG gene polymorphisms have been
shown to independently predict levels of both free
(rs6259) and total T (rs1799941) at least in aging
men [13]. Recently, SRD5A2 polymorphisms were
also shown to inﬂuence semen quality [14].
In the present study, we attempted to establish
empirical support for the hypothesis of T involve-
ment in the regulation of ejaculatory function in
humans. Based on previous empirical ﬁndings [7],
we expected levels of salivary T to be associated
with shorter ejaculation latency time (ELT). In
order to elucidate potential agents that could mod-
erate the association between T and ELT, and
based on ﬁndings in the literature, we decided to
investigate whether a total of six sex steroid-
related functional genetic polymorphisms (two
androgen receptor gene-related, two 5-alpha-
reductase gene-related [SRD5A2], and two sex
hormone-binding globulin [SHBG] gene-related)
had such interactive effects with T on ELT. We
also wanted to investigate whether any of these
polymorphisms had a direct main effect on ELT.
Materials and Methods
Participants
In the present study, we started out using a sample
of 3,331 male twin individuals and brothers of
twins, who had participated in the Genetics of
Sexuality and Aggression study, a population-
based study of Finnish twins and siblings of twins
stemming from a data collection carried out in
2006. The overall response rate for this data col-
lection was 45%. Data were collected through two
channels: postal mail and a secure, online ques-
tionnaire (participants were free to choose
between these two options). Individuals who had
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missing values on more than 50% of the items
measuring ejaculatory function were excluded
from further analyses, resulting in a sample of
1,429 men (M = 26.9 years, SD = 4.7, range
18–45). Genotype information was available for at
least 1,345 of these men (the n ﬂuctuated some-
what between the different polymorphisms
because of individual occasions of genotyping
failure). Hormone samples were available for 384
men who had also responded to questionnaire
items regarding ejaculatory function. All partici-
pants provided written informed consent. The
data collection procedures have been more exten-
sively elaborated elsewhere [15,16].
DNA Extraction and Genotyping
One androgen receptor gene tandem repeat poly-
morphism (arCAG), one androgen receptor gene
(AR) single nucleotide polymorphism (SNP), two
sex hormone-binding globulin gene (SHBG) SNPs,
and two steroid 5-alpha reductase gene (SRD5A2)
SNPs were genotyped using saliva samples (see
Table 1). Saliva samples were collected using the
OrageneTM (DNAGenotek, Inc.,Ontario,Canada)
DNA self-collection kits that were posted to the
participants and returned by them by mail. The
participants were instructed to follow the manufac-
turer’s instructions in collecting the samples and to
deposit approximately 2 mL of saliva into the col-
lection cup. When an adequate sample was col-
lected, the cap was placed on the cup and closed
ﬁrmly. The collection cup is designed so that a
stabilizing solution from the cap is released when
closed. This solution mixes with the saliva and
stabilizes the saliva sample for long-term storage at
room temperature or in low-temperature freezers.
Genotyping of SNPs was conducted by LGC
Genomics (formerly KBiosciences) in the United
Kingdom (http://www.lgcgenomics.com) using the
KASPar chemistry, a competitive allele speciﬁc
polymerase chain reaction (PCR) SNP genotyping
system performed with Förster resonance energy
transfer quencher cassette oligos.
The PCR of the CAG repeat in the AR was
performed in a total volume of 15 μL containing
about 50 ng DNA, 0.5 U HotStarTaq DNA poly-
merase (Qiagen, Limburg, the Netherlands), and
0.2 μM each of the following primers: 5′-GTG
CGCGAAGTGATCCAG A-3′ and 5′-GTTTCC
TCATCCAGGACCAGGTA-3′, with the for-
ward primer ﬂuorescently labeled with 6-
Carboxyﬂuorescein. Nucleotides promoting the
nontemplated addition of adenine by Taq DNA
polymerase were added to the 5′ end of the reverse
primer [17]. The thermal cycling was performed
with the following temperature proﬁle: 95°C for 15
minutes followed by 35 cycles of 95°C for 30
seconds, 57°C for 30 seconds, and 72°C for 30
seconds, with a ﬁnal incubation at 72°C for 7
minutes. We analyzed the ﬂuorescently labeled
DNA fragments by size with automated capillary
electrophoresis using the 3,730 Genetic Analyzer
(Applied Biosystems/Life Technologies, Carlsbad,
CA, USA). The actual number of repeats corre-
sponding to a speciﬁc fragment length was deter-
mined by sequencing (see Ref. 18).
Hormone Analyses
The participants received a Salivette®
(SARSTEDT AG & Co., Nümbrecht, Germany)
hormone sampling kit by mail and were instructed
to provide a saliva sample for hormone analyses in
Table 1 Descriptive statistics for the androgen-related single nucleotide polymorphisms
Gene Polymorphism Genotype Frequency (%) HWE χ2
AR rs6152 G 1,208 (85.7) N/A (monoallelic)
A 202 (14.3)
SRD5A2 rs2208532 A:A 487 (17.9) 3.1 n.s.
A:G 650 (46.4)
G:G 263 (18.8)
rs523349 C:C 693 (48.9) 1.33 n.s.
C:G 582 (41.1)
G:G 141 (10.0)
SHBG rs1799941 G:G 769 (54.6) 1.49 n.s.
A:G 531 (37.7)
A:A 108 (7.7)
rs6259 G:G 1,210 (84.9) 0.01 n.s.
A:G 206 (14.5)
A:A 9 (0.6)
Notes: The AR gene is located on the X chromosome, thus males carry only one allele of the AR polymorphism.
A = adenine; G = guanine; T = thymine; C = cytosine; AR = androgen receptor; SRD5A2 = 5-alpha reductase type 2; SHBG = sex hormone-binding globulin;
HWE = Hardy–Weinberg equilibrium; n.s. = not significant.
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the morning after waking up before brushing their
teeth, or drinking or eating anything, preferably
prior to 9 am. Samples were collected using a
cotton bar, which the participants were instructed
to chew for at least 1 minute (the instruction leaﬂet
speciﬁed that the cotton bar should preferably be
completely soaked in saliva). They were informed
that they could smoke prior to providing the
sample, but that they should take any medication
only afterward. A return express mail envelope was
provided for returning the sample. The partici-
pants also provided information on a number of
variables that could affect their testosterone levels.
In total, 461 men provided analyzable saliva
samples (note that only 384 of these had com-
pleted the questionnaires regarding ejaculatory
function). Salivary testosterone levels (equivalent
with free T) were determined by a modiﬁed tes-
tosterone RIA (Spectria testosterone RIA; Orion
Diagnostica, Espoo, Finland), as previously
described for sera determination [19]. The lower
limit of detection was 0.030 nmol/L, and the lower
limit of quantitation was 0.100 nmol/L. For saliva,
the intra-assay coefﬁcient of variation (CV) was
22% for concentrations of 0.170 nmol/L (n = 20).
The interassay CVs were 21% for 0.150 nmol/L
and 18% for 0.280 nmol/L (determined as a dupli-
cate in 20 assays). The total analytical imprecision
were 24% for 0.150 nmol/L and 20% for
0.280 nmol/L. For evaluation of repeated thawing,
saliva samples were thawed/ frozen seven times. It
was found that the testosterone concentration was
not affected by repeated freeze/thaw cycles. The
modiﬁed RIA is an accredited assay by Swedish
Board for Accreditation and Conformity Assess-
ment (SWEDAC) quality control agency in
Sweden, SS-EN ISO 15189 (no. 1899).
The overall mean T level was 0.280
(SD = 0.145) nmol/L. Levels below 0.030 nmol/L
were recorded to zero in order to reduce error
variance. Of the samples, 88.6% were frozen the
same day the samples were taken and an additional
8.4% the day after the samples were taken. The
rest of the samples (3.0%) were frozen between 3
and 9 days after the sample was taken. The time
that had passed since the sample taking was not
related to the T level (P < 0.936). Taking the
sample before or after 9 am was not related to T
levels (P < 0.823). Smoking prior to giving the
sample was reported by 5.8% of the men and was
not related to T levels (P < 0.651). Those who
reported consuming alcohol during the 24 hours
preceding the saliva sample were 22.9% of the
men. Men who had consumed alcohol on the day
before had signiﬁcantly lower T levels (Mnmol/L =
0.258, SE = 0.013) compared with men who
had not consumed alcohol (Mnmol/L = 0.288,
SE = 0.008, Wald χ2[1] = 3.90, P < 0.048).
Assessment of Ejaculation Latency Time
We used one self-reported Likert-type variable to
measure ELT. The question and its response
options were as follows: “On average, during inter-
course, how much time elapses between when you ﬁrst
enter your partner (vaginally or anally) with your penis
and when you ﬁrst ejaculate?” (i) I usually do not
ejaculate; (ii) more than 10 minutes; (iii) between 5
and 10 minutes; (iv) between 1 and 5 minutes; (v)
less than 1 minute. To avoid heterosexist bias and
exclusion of both female–male and male–male anal
intercourse, a gender-neutral deﬁnition of ELT
inclusive of anal intercourse was used. This ques-
tion has been shown to have a good correlation
with stopwatch measured ELT in other samples
available to the researchers (r = −0.71, P < 0.001).
This question has also been used as a proxy
measure of PE in previous studies (e.g., [20]).
Statistical Analyses
All analyses were computed with the Generalized
Estimating Equations module in PASW 18.0. This
model appropriately takes into account between-
subject dependence, which was necessary since the
sample in the present study consisted of twins and
brothers of the twins. For individuals who had
responded to more than 50% of the questionnaire
items, missing values were imputed using the
expectation maximization method of the Missing
Value Analysis procedure of PASW 18.0. Linear
and binary models were ﬁtted to the data as appro-
priate (i.e., binary models when the dependent
variable was dichotomous, such as in the extreme
group analyses). Individual values for each item
were imputed using information from the same
individual’s responses on all items in the scale
measuring ejaculatory function. In order to mini-
mize statistical interference, we strived to keep the
number of covariates as low as possible. Therefore,
all analyses involving genetic polymorphisms were
conducted separately for each polymorphism. For
all analyses involving T, we controlled for effects
of age and body mass index, since these have been
shown to have a signiﬁcant association with T
levels [13,21]. Since the arCAG tandem repeat
polymorphism is located on the X chromosome,
and men thus carry only one allele, the arCAG
polymorphism was analyzed as a continuous vari-
able. Continuous variables were centralized by
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subtracting the mean from the variable prior to
interaction effect analyses.
In order to investigate whether T plays a more
prominent role at the extreme ends of the ejacula-
tion latency continuum (as suggested by Corona
et al. [7]), we conducted two different extreme
group analyses. First, we compared T level of men
with the highest score on the ELT variable (n = 8;
this group represents individuals who reported
they usually ejaculated in less than 1 minute during
penetrative intercourse) to T levels of men who
reported that they usually do not ejaculate during
penetrative intercourse (n = 15). Next, we broad-
ened the criteria and compared groups of men who
reported that they typically ejaculated within
either 1 minute or between 1 and 5 minutes during
penetrative intercourse (n = 131) to men who
reported that they typically ejaculated after more
than 10 minutes or not at all (n = 102).
Ethics Statement
Self-collected saliva samples were used for all
DNA and hormone analyses. These were posted to
the participants, who collected the samples them-
selves, and returned them by mail. The voluntary
nature of the study was clearly explained to all
participants in a cover letter, and written informed
consent was obtained by all. The research plan was
approved by the Ethics Committee of the Abo




The mean level of free testosterone in the sample
was 0.28 nmol/L, ranging from <0.03 to 1.35,
which is comparable with previous studies con-
ducted on samples of men of similar age [19,22].
Some 1,345 individuals had valid genotype infor-
mation for the arCAG repeat polymorphism, and
the number of repeats varied between 6 and 33
(M = 20, SD = 8.51; Md = 20 [161 occurrences],
most common genotype = 19 repeats [260 occur-
rences]). Descriptive statistics for the ﬁve SNPs
are presented in Table 1. The variable measuring
ELT had a mean of 2.85 (SD = 0.83, range 1–5)
after imputation, with higher values indicating
shorter ELTs. Note that this variable uses ordinal
classes, and is thus not to be interpreted as a mean
number of minutes.
Hormonal and Genotypic Analyses
We found no signiﬁcant association between
levels of salivary T and ELT (Wald χ2[1] = 0.015,
P = 0.904). Next, we investigated whether T plays
a more prominent role at the extreme ends of the
ejaculation latency continuum (as suggested by
Corona et al. [7]). T levels of men with the highest
score on the ELT variable were compared with T
levels of men who reported that they usually do
not ejaculate during penetrative intercourse;
however, we found no signiﬁcant associations
(Wald χ2[1] = 0.332, P = 0.564). We then repeated
this analysis using broadened criteria (i.e., compar-
ing groups of men typically ejaculating within
either 1 minute or between 1 and 5 minutes during
penetrative intercourse with men typically ejacu-
lating after more than 10 minutes or not at all) but
found no signiﬁcant effects of T in this analysis
either (Wald χ2[1] = 0.047, P = 0.827).
We proceeded to investigate whether any of the
androgen-related genetic polymorphisms had a
main effect on ELT. As can be seen in Table 2, the
SRD5A2 linked polymorphism rs2208532 had a
nominally signiﬁcant main effect on ELT;
however, this effect was not signiﬁcant after cor-
rection for multiple testing (Bonferroni correction
for 12 tests gives an alpha threshold of P = 0.0042).
Next, we conducted analyses to elucidate whether
any of these six polymorphisms moderated the
association between T and ELT. As can be seen in
Table 3, we found a signiﬁcant interaction effect
between the SHBG rs1799941 SNP and T levels
on ELT (P = 0.003); this interaction was signiﬁ-
cant after Bonferroni correction.
Next, we conducted further analyses on the
SHBG-linked SNP rs1799941 in order to clarify
the direction of the interaction effects. As can be
seen in Table 4, individuals carrying the A:A geno-
type had a signiﬁcant association between T levels
and ELT, so that higher T levels were associated
with longer ELTs, whereas there were no such
associations for the other genotype groups.
Table 2 Associations between androgen-related genetic
polymorphisms and ejaculatory function
Gene Polymorphism Wald χ2 df P
AR CAG repeat 0.103 1 0.749
rs6152 0.095 1 0.758
SRD5A2 rs2208532 6.952 2 0.029*
rs523349 1.698 2 0.428
SHBG rs1799941 0.096 2 0.953
rs6259 0.192 2 0.908
AR = androgen receptor, SRD5A2 = 5-alpha reductase type 2, SHBG = sex
hormone-binding globulin; df = degrees of freedom.
*Not significant after correction for multiple testing (Bonferroni adjusted P for
12 tests = 0.004). Age and body mass index (kg/m2) were used as covariates
in all analyses.
Testosterone, Polymorphisms, and Ejaculation 111
Sex Med 2014;2:107–114© 2014 The Authors. Sexual Medicine published by Wiley Periodicals, Inc.
on behalf of International Society for Sexual Medicine.
Discussion
In the present study, we attempted to reassess pre-
vious ﬁndings regarding an association between
ELTandT levels, as previously reported byCorona
et al. [7] and Lotti et al. [8]. However, we found no
such association. Also, we detected no signiﬁcant
differences between extreme groups of individuals
withELTs of less than aminute and individuals who
usually do not ejaculate during intercourse. A plau-
sible explanation for this is related to insufﬁcient
statistical power: our sample size was considerably
smaller than that of Corona et al. [7], and we
used a population-based approach rather than
oversamplingPEpatients, and thus our samplemay
be underpowered to detect this association. Never-
theless, while there may be a true association
between T levels and ELT, it is likely that any such
association is of small effect size. It should also be
noted that theT values of the individuals with PE in
Corona et al.’s [7] study were within what is usually
considered the normal range, suggesting that most
PE cases are not caused by abnormalTmetabolism.
Another possible explanation for our failure to rep-
licate the results of Corona et al. [7] is that we used
saliva samples tomeasureT levels, whereas Corona
et al. used blood samples. T measures derived from
saliva samples have been shown to be unreliable
under some circumstances (see, e.g., Ref. 23);
however, these obstacles can be overcome (see
further elaboration on this in the Limitations
section at the end of the Discussion). Furthermore,
variation in T levels has been shown to be highly
variable as a function of environmental factors (e.g.,
T levels have been shown to decrease in supporters
of the losing team, and increase in supporters of the
winning team, when tested in a sample of associa-
tion football spectators [24]). Thus, because PE has
been repeatedly associated with decreased psycho-
logical well-being and sexual distress [25], it is
possible that T variability is an effect of variability
in ejaculatory function rather than the other way
around. T could also possibly affect ejaculatory
function through complex interactions with
thyroid hormones (e.g., Refs. 7 and 26–29).
At nominal level, we found an association
between one SNP and ELT, namely, the SRD5A2-
receptor linked rs2208532. However, this associa-
tion did not survive correction for multiple tests,
and therefore this association should be interpreted
with caution until replicated in larger samples. In
the interaction analyses, we detected an association
that survived Bonferroni correction for 12 tests;
so that the SHBG-linked rs1799941 SNP moder-
ated the association betweenTandELT (A:Ageno-
type carriers had a negative association between T
andELT, i.e., shorter ELTs as a function of decreas-
ing T levels, whereas there was no association
between T and ELT for the heterozygotes or indi-
viduals homozygous for the G allele). Interestingly,
there is rather robust evidence for the rs1799941
SNP’s impact on both circulating SHBG and T
levels in men, so that carriers of the A:A genotype
display circulating SHBG levels of a magnitude of
0.4 standard deviations higher and also higher
levels of T [30–32]. Our ﬁnding is therefore quite
puzzling, as we would have expected a different
direction of effects (e.g., so that A:A genotype car-
riers would have had a positive, not negative, asso-
ciation between T and ELT). It should be borne in
mind that the number of rs1799941 A:A genotype
Table 3 Interaction effects between androgen-related
genetic polymorphisms and salivary testosterone on
ejaculation latency time
Gene Polymorphism Wald χ2 df P
AR CAG repeat 0.004 1 0.950
rs6152 0.254 2 0.614
SRD5A2 rs2208532 3.552 2 0.169
rs523349 1.314 2 0.518
SHBG rs1799941 11.424 2 0.003*
rs6259 5.373 2 0.068
Note: Testosterone was AR = androgen receptor, SRD5A2 = 5-alpha
reductase type 2, SHBG = sex hormone-binding globulin; df = degrees of
freedom.
*Significant after Bonferroni correction for 12 tests (adjusted significance
threshold P = 0.004). Age and body mass index (kg/m2) were used as
covariates in all analyses.
Table 4 Associations between salivary testosterone and ejaculation latency time by genotype group of the sex
hormone-binding globulin gene-linked polymorphism rs1799941
rs1799941 genotype
group (n) r B (95% Wald CI) SE
Wald χ2
(1 df) P
A:A (28) −0.495** −2.481 (−3.974 to −0.989) 0.761 10.624 0.001
G:A (128) 0.050 0.316 (−0.841 to 1.472) 0.590 0.286 0.593
G:G (183) 0.068 0.487 (−0.670 to 1.645) 0.590 0.681 0.409
A = adenine; G = guanine; SE = standard error; CI = confidence interval, df = degrees of freedom, r = Pearson correlation. **P < 0.01. Higher values on the variable
measuring ejaculation latency time indicate shorter ejaculation latencies. Age and body mass index (kg/m2) were used as covariates in all analyses.
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carriers with available T data was only 28, and thus
we advise caution in the interpretation of this result.
Nevertheless, the rs1799941 SNP could be consid-
ered an interesting target for further investigation.
The following limitations should be considered
when assessing our results. First, our sample size
was relatively small, which has implications espe-
cially for detecting genetic effects, which are
usually of very small effect size. Second, our study
relied on self-reported rather than stopwatch mea-
sured ejaculatory latency; however, it should be
noted that self-reported and stopwatch measured
ejaculatory latencies have been shown to be inter-
changeable [33]. Third, concerns have been raised
in the literature regarding the comparability of T
measures derived from saliva and blood. Saliva
sampling comes with increased risks of error par-
ticularly because saliva samples are more vulner-
able to contamination (e.g., through blood
[plasma] leakage into the saliva [23]). However,
studies also show that saliva and blood measured T
levels are comparable if necessary quality checks
are performed [23,34]. The modiﬁed assay used in
the present study is, as noted in the Methods
section, accredited by the SWEDAC quality
control agency in Sweden. In addition, T levels
measured in the present study are comparable with
T levels measured in men of similar age in studies
using different samples (e.g., [22]). We do,
however, advise caution when comparing our
results regarding associations with T with similar
results in other studies that have used blood as
sampling medium.
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